FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis
- PMID: 23922481
- PMCID: PMC3732856
- DOI: 10.3748/wjg.v19.i29.4808
FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis
Abstract
Aim: To investigate the potential role of positron emission tomography (PET) in the diagnosis, staging and prognosis predicting of pancreatic carcinoma (PC).
Methods: A systematic review of relevant literatures in PubMed, Embase and Cochrane Library was performed. The sensitivity and specificity of diagnostic and staging studies, and HRs for prognosis predicting studies were pooled. The bivariate model was used for diagnostic studies and the random-effect model for prognostic studies. Heterogeneity between included studies was tested using χ(2) test, and subgroup analysis was performed to explain the heterogeneities. All of the calculations were performed using Stata version 11.0.
Results: A total of 39 studies were included. The pooled sensitivity of PET in diagnosing PC (30 studies, 1582 patients), evaluating N stating (4 studies, 101 patients) and liver metastasis (7 studies, 316 patients) were 0.91 (95%CI: 0.88-0.93), 0.64 (95%CI: 0.50-0.76), and 0.67 (95%CI: 0.52-0.79), respectively; and the corresponding specificity was 0.81 (95%CI: 0.75-0.85), 0.81 (95%CI: 0.25-0.85), and 0.96 (95%CI: 0.89-0.98), respectively. In prognosis analysis (6 studies, 198 patients), significant difference of overall survival was observed between high and low standardized uptake value groups (HR = 2.39, 95%CI: 1.57-3.63). Subgroup analysis showed that PET/CT was more sensitive than PET alone in evaluating liver metastasis of PC, 0.82 (95%CI: 0.48-0.98) and 0.67 (95%CI: 0.52-0.79), respectively.
Conclusion: PET can be used as a valuable diagnostic and predictive tool for PC, but its effect in the staging of PC remains indeterminate.
Keywords: Diagnosis; Meta-analysis; Pancreatic carcinoma; Positron emission tomography; Prognosis; Staging.
Figures





Similar articles
-
The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.Hepatogastroenterology. 2014 Oct;61(135):2102-9. Hepatogastroenterology. 2014. PMID: 25722999
-
Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.Eur J Radiol. 2011 Apr;78(1):142-50. doi: 10.1016/j.ejrad.2009.09.026. Epub 2009 Oct 23. Eur J Radiol. 2011. PMID: 19854016
-
Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.Eur J Surg Oncol. 2014 Jul;40(7):794-804. doi: 10.1016/j.ejso.2014.03.016. Epub 2014 Apr 3. Eur J Surg Oncol. 2014. PMID: 24755095 Review.
-
The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.J Clin Gastroenterol. 2006 Nov-Dec;40(10):923-9. doi: 10.1097/01.mcg.0000225672.68852.05. J Clin Gastroenterol. 2006. PMID: 17063113
-
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis.J Hepatol. 2019 Jul;71(1):115-129. doi: 10.1016/j.jhep.2019.01.038. Epub 2019 Feb 21. J Hepatol. 2019. PMID: 30797051
Cited by
-
Positron Emission Tomography (PET) in Oncology.Cancers (Basel). 2014 Sep 29;6(4):1821-89. doi: 10.3390/cancers6041821. Cancers (Basel). 2014. PMID: 25268160 Free PMC article. Review.
-
Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.Medicine (Baltimore). 2015 Sep;94(36):e1462. doi: 10.1097/MD.0000000000001462. Medicine (Baltimore). 2015. PMID: 26356700 Free PMC article.
-
αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin.Front Nucl Med. 2024 Nov 15;4:1487602. doi: 10.3389/fnume.2024.1487602. eCollection 2024. Front Nucl Med. 2024. PMID: 39618940 Free PMC article.
-
Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.Adv Sci (Weinh). 2021 Feb 12;8(7):2002545. doi: 10.1002/advs.202002545. eCollection 2021 Apr. Adv Sci (Weinh). 2021. PMID: 33854877 Free PMC article. Review.
-
A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables.Phys Med Biol. 2017 Apr 7;62(7):2658-2674. doi: 10.1088/1361-6560/aa5d42. Epub 2017 Jan 31. Phys Med Biol. 2017. PMID: 28140359 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
-
- American Cancer Society. Pancreatic cancer. Available from: http://www.cancer.org.
-
- Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology. 2005;5:576–590. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical